BioCardia, Inc. (BCDA)
NASDAQ: BCDA · IEX Real-Time Price · USD
0.376
-0.018 (-4.52%)
At close: May 1, 2024, 4:00 PM
0.360
-0.016 (-4.25%)
Pre-market: May 2, 2024, 5:20 AM EDT
BioCardia Revenue
In the year 2023, BioCardia had annual revenue of $477.00K, a decrease of -64.72%. Revenue in the quarter ending December 31, 2023 was $13.00K, a -87.74% decrease year-over-year.
Revenue (ttm)
$477.00K
Revenue Growth
-64.72%
P/S Ratio
21.19
Revenue / Employee
$29,813
Employees
16
Market Cap
10.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
Dec 31, 2011 | 12.00K | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Telesis Bio | 27.51M |
Guardion Health Sciences | 12.25M |
Aeterna Zentaris | 4.50M |
Addex Therapeutics | 1.96M |
Inhibikase Therapeutics | 260.50K |
BCDA News
- 22 hours ago - BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes - GlobeNewsWire
- 6 days ago - BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort - GlobeNewsWire
- 5 weeks ago - BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results - GlobeNewsWire
- 6 weeks ago - BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 - GlobeNewsWire
- 7 weeks ago - BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - GlobeNewsWire
- 7 weeks ago - BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study - GlobeNewsWire
- 2 months ago - BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure - GlobeNewsWire
- 2 months ago - BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA - GlobeNewsWire